A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Phase
3Span
160 weeksSponsor
Samsung Bioepis Co., Ltd.Tachikawa
Recruiting
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
Phase
1/2Span
292 weeksSponsor
Incyte Biosciences Japan GKTachikawa
Recruiting
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
Phase
2Span
72 weeksSponsor
Janssen Research & Development, LLCTachikawa
Recruiting
1-3 of 3